{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:56:29Z","timestamp":1792529789108,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tolvaptan is the only available disease-modifying treatment for autosomal dominant polycystic kidney disease (ADPKD). Prior to October 2020 access to tolvaptan in Australia was restricted by a controlled monitoring and distribution program called IMADJIN\u00ae. Focusing on hepatic safety, the IMADJIN\u00ae program collected real-world data on patients with ADPKD. A retrospective, secondary data analysis of the IMADJIN\u00ae dataset was undertaken to determine the time to all-cause discontinuation of tolvaptan in Australia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Demographic and treatment data from 17 September 2018 to 30 September 2020 were extracted from the IMADJIN\u00ae dataset. Treatment persistence was analyzed using Kaplan-Meier methods, and Cox\u2019s proportional hazard models were used to analyze differences in treatment persistence by age, sex and location.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four hundred seventy-nine patients with ADPKD were included in the analysis. After a median follow-up of 12.0\u2009months (95% confidence interval [CI] 2.6, 23.4), the Kaplan-Meier estimation of 12-month persistence was 76.7% (95% CI 72.2, 80.5%). 114 (23.8%) patients discontinued treatment; sex, state, and remoteness did not significantly affect treatment persistence. Patients in the youngest tertile were more likely to discontinue compared to older ages (<jats:italic>p<\/jats:italic>\u2009=\u20090.049). Reasons for discontinuation included: aquaretic tolerability (4.2%), hepatic adverse events (abnormal liver function tests) (2.1%), disease progression (1.5%), and acute kidney injury (0.2%). Patients with a lack of aquaretic tolerance had shorter time to discontinuation. Hepatic toxicity events were initially observed 3 months after tolvaptan initiation and were less prevalent over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Persistence to tolvaptan in the real-world IMADJIN\u00ae dataset was 76%. Discontinuation due to hepatic events was low. Prescribers should take extra care when initiating treatment in younger patients as they are more likely to discontinue tolvaptan compared to older individuals. Nevertheless, the precise reason for this observation remains to be elucidated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02607-4","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T06:53:56Z","timestamp":1638428036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN\u00ae dataset"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8922-7583","authenticated-orcid":false,"given":"Mark","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique Franca","family":"Gois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda E.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8437-4373","authenticated-orcid":false,"given":"Michelle H. T.","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg W.","family":"Van Wyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"1","key":"2607_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJ, Torres VE. Polycystic kidney disease. Nature Reviews Disease Primers. 2018;4(1):1\u201324.","journal-title":"Nature Reviews Disease Primers"},{"key":"2607_CR2","unstructured":"PKD Australia. What is ADPKD? Access date: 04 February 2021. Available at: https:\/\/pkdaustralia.org\/adpkd\/"},{"issue":"8","key":"2607_CR3","first-page":"1356","volume":"32","author":"CJ Willey","year":"2017","unstructured":"Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2017;32(8):1356\u201363.","journal-title":"Nephrol Dial Transplant"},{"issue":"9569","key":"2607_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet"},{"issue":"20","key":"2607_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"issue":"25","key":"2607_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"key":"2607_CR7","doi-asserted-by":"crossref","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant. 2017;33(3):477-489.","DOI":"10.1093\/ndt\/gfx043"},{"key":"2607_CR8","doi-asserted-by":"crossref","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O: Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 2021.","DOI":"10.2215\/CJN.10250620"},{"key":"2607_CR9","unstructured":"Otsuka Pharmaceutical Australia Pty Ltd. Australian Product Information JINARC\u00ae (tolvaptan) tablets Access date: 06 January 2021. Available at: www.ebs.tga.gov.au\/"},{"issue":"5","key":"2607_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.0306-5251.2003.02054.x","volume":"57","author":"RJ MacFadyen","year":"2004","unstructured":"MacFadyen RJ, Gorski JC, Brater DC, Struthers AD. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol. 2004;57(5):622\u201331.","journal-title":"Br J Clin Pharmacol"},{"key":"2607_CR11","doi-asserted-by":"crossref","unstructured":"McFarlane P, Parfrey P, Bichet DG, Bergeron L, Laplante A. Abstract PO1537 Canadian real-world assessment of Tolvaptan in ADPKD: C-Major study and safety monitoring and distribution program. American Society of Nephrology Kidney Week. Digital Meeting 2020.","DOI":"10.1016\/j.ekir.2021.03.353"},{"key":"2607_CR12","unstructured":"Australian Bureau of Statistics. The Australian Statistical Geography Standard (ASGS) remoteness structure Access date: 18 May 2021. Available at: https:\/\/www.abs.gov.au\/websitedbs\/D3310114.nsf\/home\/remoteness+structure"},{"key":"2607_CR13","unstructured":"Australian Bureau of Statistics. National, state and territory population Access date: 04 February 2021. Available at: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/jun-2020"},{"key":"2607_CR14","first-page":"1121","volume":"10","author":"VT Truong","year":"2016","unstructured":"Truong VT, Moisan J, Kr\u00f6ger E, Langlois S, Gr\u00e9goire J-P. Persistence and compliance with newly initiated antihypertensive drug treatment in patients with chronic kidney disease. Patient preference and adherence. 2016;10:1121.","journal-title":"Patient preference and adherence"},{"issue":"1","key":"2607_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18553\/jmcp.2020.26.1.67","volume":"26","author":"D Gor","year":"2020","unstructured":"Gor D, Lee TA, Schumock GT, Walton SM, Gerber BS, Nutescu EA, et al. Adherence and persistence with DPP-4 inhibitors versus pioglitazone in type 2 diabetes patients with chronic kidney disease: a retrospective claims database analysis. Journal of Managed Care & Specialty Pharmacy. 2020;26(1):67\u201375.","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"issue":"8","key":"2607_CR16","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s11739-019-02100-9","volume":"14","author":"C Godino","year":"2019","unstructured":"Godino C, Melillo F, Rubino F, Arrigoni L, Cappelletti A, Mazzone P, et al. Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. Intern Emerg Med. 2019;14(8):1259\u201370.","journal-title":"Intern Emerg Med"},{"key":"2607_CR17","unstructured":"Deapartment of Health Australian Government. Tolvaptan PBS Listing Access date: 01 April 2021. Available at: https:\/\/www.pbs.gov.au\/medicine\/item\/11600M-11602P"},{"issue":"6","key":"2607_CR18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","volume":"2","author":"O Devuyst","year":"2017","unstructured":"Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD. Tolerability of Aquaretic-related symptoms following Tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4. Kidney Int Rep. 2017;2(6):1132\u201340.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"2607_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38(11):1103\u201313.","journal-title":"Drug Saf"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02607-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02607-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T06:54:41Z","timestamp":1638428081000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02607-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2607"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02607-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with all relevant guidelines and regulations. The secondary data analysis of the IMADJIN\u00ae dataset, including an informed consent waiver approval, was approved by the Royal Perth Hospital Human Research Ethics Committee (Approval Number: RGS0000003858), Perth, Western Australia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT has received lecture fees and advisory board fees, plus international research funding for the TEMPO and OLE studies. PFG has no competing interests to declare. BEB declares medical writing fees and statistical consulting fees paid to WriteSource Medical Pty Ltd. for services provided to the following pharmaceutical companies: AbbVie, Actelion, Alexion, Bayer, BMS, Ferring, George Clinical, Hartmann, Janssen-Cilag Australia, Lilly, Lundbeck, Medlab, Merck, Novartis, Nucleus Network, Pfizer, Pharmaxis, Roche, Sandoz, Sanofi, UCB. MHTT is an employee of Otsuka Australia Pharmaceutical Pty Ltd. GWVW declares strategic and medical consulting fees paid to AIH Consulting Pty Ltd., by Otsuka Australia Pharmaceutical Pty Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}